LH · Laboratory Corp of America Holdings - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.54B | - | $3.56B | $3.53B | $3.35B | - | $3.28B | $3.22B | $3.18B | - |
| Cost of Revenue | $2.52B | - | $2.54B | $2.48B | $2.40B | - | $2.38B | $2.29B | $2.28B | - |
| Gross Profit | $1.01B | - | $1.03B | $1.05B | $948.00M | - | $904.40M | $926.40M | $897.30M | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $551.00M | - | $552.40M | $579.30M | $546.00M | - | $568.60M | $557.80M | $508.40M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $173.30M | - | - | - | $166.80M | - | - | - | $154.50M | - |
| Operating Income | $380.80M | - | $396.60M | $394.50M | $326.00M | - | $254.10M | $294.80M | $321.30M | - |
| Interest Expense | $55.10M | - | $56.00M | $57.10M | $56.00M | - | $50.40M | $47.60M | $46.90M | - |
| Income Tax | $41.70M | - | $75.50M | $66.40M | $62.20M | - | $41.00M | $62.10M | $69.10M | - |
| Net Income | $277.80M | - | $261.10M | $237.90M | $212.80M | - | $169.30M | $205.30M | $228.00M | - |
| EPS - Basic | $3.37 | - | $3.14 | $2.85 | $2.54 | - | $2.02 | $2.44 | $2.71 | - |
| EPS - Diluted | $3.35 | - | $3.12 | $2.84 | $2.52 | - | $2.00 | $2.43 | $2.69 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $981.10M | $532.30M | $598.10M | $647.30M | $369.40M | $1.52B | $1.52B | $265.10M | $99.30M | $536.80M |
| Accounts Receivable | $2.29B | $2.10B | $2.11B | $2.12B | $2.12B | $1.94B | $2.06B | $2.09B | $2.08B | $1.91B |
| Inventory | $497.70M | $534.70M | $521.50M | $508.10M | $488.30M | $493.20M | $483.10M | $441.80M | $475.00M | $474.60M |
| Accounts Payable | $695.70M | $840.80M | $668.50M | $793.00M | $717.90M | $875.80M | $660.90M | $760.60M | $695.50M | $827.50M |
| Current Assets | $4.56B | $4.02B | $4.08B | $4.09B | $3.79B | $4.81B | $4.91B | $3.57B | $3.46B | $3.77B |
| Total Assets | $19.09B | $18.39B | $18.26B | $18.06B | $17.60B | $18.38B | $18.61B | $16.71B | $16.53B | $16.73B |
| Current Liabilities | $2.64B | $2.82B | $2.63B | $2.72B | $2.06B | $3.33B | $3.41B | $4.06B | $3.94B | $3.23B |
| Long-term Debt | $5.83B | $5.08B | $5.08B | $5.08B | $5.57B | $5.33B | $5.35B | $3.05B | $3.05B | $4.05B |
| Total Liabilities | $10.34B | $9.76B | $9.55B | $9.57B | $9.28B | $10.31B | $10.43B | $8.69B | $8.56B | $8.83B |
| Stockholders' Equity | $8.73B | $8.62B | $8.70B | $8.47B | $8.31B | $8.05B | $8.17B | $8.01B | $7.96B | $7.88B |
| Retained Earnings | $8.78B | $8.64B | $8.70B | $8.50B | $8.46B | $8.30B | $8.28B | $8.18B | $8.06B | $7.89B |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $191.50M | - | - | - | $18.50M | - | - | - | ($29.80M) | - |
| Investing Cash Flow | ($322.10M) | - | - | - | ($336.00M) | - | - | - | ($393.10M) | - |
| Financing Cash Flow | $580.50M | - | - | - | ($839.70M) | - | - | - | ($11.70M) | - |
| CapEx | $121.00M | - | - | - | $126.00M | - | - | - | $133.80M | - |
| Free Cash Flow | $70.50M | - | - | - | ($107.50M) | - | - | - | ($163.60M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 28.7% | - | 28.8% | 29.7% | 28.3% | - | 27.6% | 28.8% | 28.2% | - |
| Operating margin | 10.8% | - | 11.1% | 11.2% | 9.7% | - | 7.7% | 9.2% | 10.1% | - |
| EBITDA margin | 15.7% | - | - | - | 14.7% | - | - | - | 15.0% | - |
| Net margin | 7.9% | - | 7.3% | 6.7% | 6.4% | - | 5.2% | 6.4% | 7.2% | - |
| Free cash flow margin | 2.0% | - | - | - | -3.2% | - | - | - | -5.2% | - |
| FCF / Net income | 0.25 | - | - | - | -0.51 | - | - | - | -0.72 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 15.6% | - | 15.5% | 16.4% | 16.3% | - | 17.3% | 17.3% | 16.0% | - |
| Effective tax rate | 13.1% | - | 22.4% | 21.8% | 22.6% | - | 19.5% | 23.2% | 23.3% | - |
| Return on assets | 1.5% | - | 1.4% | 1.3% | 1.2% | - | 0.9% | 1.2% | 1.4% | - |
| Return on equity | 3.2% | - | 3.0% | 2.8% | 2.6% | - | 2.1% | 2.6% | 2.9% | - |
| Return on invested capital | 2.3% | - | 2.2% | 2.3% | 1.8% | - | 1.5% | 2.0% | 2.2% | - |
| Liquidity | ||||||||||
| Current ratio | 1.73 | 1.42 | 1.55 | 1.50 | 1.84 | 1.44 | 1.44 | 0.88 | 0.88 | 1.17 |
| Quick ratio | 1.54 | 1.23 | 1.35 | 1.32 | 1.60 | 1.30 | 1.30 | 0.77 | 0.76 | 1.02 |
| Cash ratio | 0.37 | 0.19 | 0.23 | 0.24 | 0.18 | 0.46 | 0.44 | 0.07 | 0.03 | 0.17 |
| Leverage | ||||||||||
| Debt / Equity | 0.67 | 0.59 | 0.58 | 0.60 | 0.67 | 0.66 | 0.66 | 0.38 | 0.38 | 0.51 |
| Debt / Assets | 0.31 | 0.28 | 0.28 | 0.28 | 0.32 | 0.29 | 0.29 | 0.18 | 0.18 | 0.24 |
| Debt / EBITDA | 10.53 | - | - | - | 11.30 | - | - | - | 6.41 | - |
| Interest coverage | 6.9x | - | 7.1x | 6.9x | 5.8x | - | 5.0x | 6.2x | 6.9x | - |
| Equity multiplier | 2.19 | 2.13 | 2.10 | 2.13 | 2.12 | 2.28 | 2.28 | 2.09 | 2.08 | 2.12 |
| Liabilities / Assets | 0.54 | 0.53 | 0.52 | 0.53 | 0.53 | 0.56 | 0.56 | 0.52 | 0.52 | 0.53 |
| Efficiency | ||||||||||
| Asset turnover | 0.19 | - | 0.20 | 0.20 | 0.19 | - | 0.18 | 0.19 | 0.19 | - |
| Inventory turnover | 5.07 | - | 4.87 | 4.88 | 4.91 | - | 4.92 | 5.19 | 4.80 | - |
| Days sales outstanding | 236d | - | 216d | 219d | 232d | - | 229d | 237d | 239d | - |
| Days inventory outstanding | 72d | - | 75d | 75d | 74d | - | 74d | 70d | 76d | - |
| Days payable outstanding | 101d | - | 96d | 117d | 109d | - | 101d | 121d | 111d | - |
| Cash conversion cycle | 207d | - | 195d | 178d | 197d | - | 202d | 186d | 204d | - |
| Valuation | ||||||||||
| P / E | 79.6x | - | 92.0x | 92.4x | 92.4x | - | 111.7x | 83.7x | 81.2x | - |
| P / B | 2.5x | - | 2.8x | 2.6x | 2.4x | - | 2.3x | 2.1x | 2.3x | - |
| P / S | 6.3x | - | 6.7x | 6.2x | 5.9x | - | 5.7x | 5.3x | 5.8x | - |
| EV / EBITDA | 48.7x | - | - | - | 50.4x | - | - | - | 45.1x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 5.8% | - | 8.6% | 9.5% | 5.3% | - | 7.4% | - | 4.7% | - |
| Revenue CAGR (3y) | 5.3% | - | -0.4% | -1.6% | - | - | -6.9% | -5.7% | -8.6% | - |
| Revenue CAGR (5y) | -3.2% | - | -1.8% | 5.0% | 3.4% | - | 2.3% | 2.3% | 2.6% | - |
| Gross profit growth (YoY) | 6.9% | - | 13.3% | 12.9% | 5.7% | - | 6.3% | - | 6.5% | - |
| Operating income growth (YoY) | 16.8% | - | 56.1% | 33.8% | 1.5% | - | 0.7% | - | 20.7% | - |
| Net income growth (YoY) | 30.5% | - | 54.2% | 15.9% | -6.7% | - | -7.6% | - | 20.7% | - |
| EPS growth (YoY) | 32.9% | - | 56.0% | 16.9% | -6.3% | - | -5.2% | - | 26.9% | - |
| EPS CAGR (3y) | 16.5% | - | -7.2% | -9.8% | - | - | -30.9% | -20.1% | -29.9% | - |
| EPS CAGR (5y) | -15.6% | - | -15.3% | 3.7% | - | - | -2.3% | 4.7% | 7.7% | - |
| FCF growth (YoY) | - | - | - | - | 34.3% | - | - | - | - | - |
| FCF CAGR (5y) | -41.9% | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 5.1% | 7.0% | 6.4% | 5.8% | 4.4% | 2.3% | 3.8% | - | -9.4% | -22.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$13.97B totalDiagnostics$10.88B · 77.8%
Biopharma Laboratory Services$3.10B · 22.2%
Peer comparison
Same SIC group: Services-Medical Laboratories
Comparing LABORATORY CORP OF AMERICA HOLDINGS against the 5 most active filers in the same SIC group.
Dividends
$2.88/share trailing 12 months · 0.0% YoY
| Ex-date | Per share |
|---|---|
| May 29, 2026 | $0.7200 |
| Feb 27, 2026 | $0.7200 |
| Nov 26, 2025 | $0.7200 |
| Aug 28, 2025 | $0.7200 |
| May 29, 2025 | $0.7200 |
| Feb 27, 2025 | $0.7200 |
| Nov 26, 2024 | $0.7200 |
| Aug 29, 2024 | $0.7200 |
| May 24, 2024 | $0.7200 |
| Feb 26, 2024 | $0.7200 |
| Nov 7, 2023 | $0.7200 |
| Aug 7, 2023 | $0.7200 |
| May 17, 2023 | $0.6186 |
| Feb 22, 2023 | $0.6186 |
| Nov 16, 2022 | $0.6186 |
| Aug 17, 2022 | $0.6186 |
| May 18, 2022 | $0.6186 |